We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Key miRNA Profiling to Boost Company Fortunes in 2012

By LabMedica International staff writers
Posted on 25 Jan 2012
The coming year is set to witness dramatic growth of biotechnology companies specializing in stem cell research and drug development.

One such company is Sistemic Ltd. (Glasgow, United Kingdom), which has planned a GBP 1 million investment program for 2012. A portion of this investment is to be covered by a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise.

Sistemic’s activities are currently focused on microRNAs (miRNAs) and miRNA profiling. MicroRNAs are seen as the master controllers of the cell and, as such, Sistemic believes they provide information on the effects within a whole cell or organism rather than an isolated pathway. This systems approach means that the data produced is more indicative of the biology and more informative of actual effect. As a result, Sistemic leverages miRNA based profiling/fingerprinting to provide information rich products to companies worldwide.

Systemic has developed proprietary statistical algorithms that robustly and with a high degree of confidence analyze changes to miRNAs when a cell is perturbed by a stimulus. Together with innovative visualization techniques, Systemic is able to generate a fingerprint of a key set of miRNAs known as “key miRNAs” (kmiRs) that represent these changes accurately.

The Sistemic methodology provides a rigorous yet rapid understanding of the biological changes that occur within a cell. Resulting data, allows companies to make well-informed decisions, in a timely fashion. This enables them to develop their cell (or stem cell) therapy accordingly.

Jim Reid, CEO of Sistemic said, “Securing this support from Scottish Enterprise is a major achievement and shows great support by the Scottish Government for what we are doing. It adds to an already successful year for Sistemic, a year, which has seen us grow sales dramatically and develop our customer base in Europe, USA, Japan, and Australia. We truly have become a global company during 2011 and we look forward to relocating in the first half of 2012 to allow this success and growth to continue. It is always an exciting opportunity to be on the lookout for new employees and we are ideally placed to recruit top talent. This type of grant support is crucial to help grow successful research focused biotech companies such as ours and we will ensure we make the most of it!”

Related Links:
Sistemic Ltd.


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
Automatic CLIA Analyzer
Shine i6000

Latest BioResearch News

Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
25 Jan 2012  |   BioResearch

Genetic Cause Identified for Severe Infant Epilepsy
25 Jan 2012  |   BioResearch

Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
25 Jan 2012  |   BioResearch